Roche touts FDA clearance for its Accu-Chek Nano SmartView blood glucose monitoring system.
Roche (PINK:RHHBY) won clearance from the U.S. Food & Drug Administration for its Accu-Chek Nano SmartView blood glucose monitoring system.
The Switzerland-based biotech builder's no code meter is smaller than a credit card that allows patients to customize test reminders, pre and post meal markers and calculate their average glucose levels.
"It is easy-to-use and will help people with diabetes regularly check their blood glucose levels before making informed therapy and lifestyle adjustments," Marc Gibeley, head of Roche Diabetes Care North America said in prepared remarks. "We look forward to its launch later this year."
The new system is part of the same product line as the Accu-Chek Aviva and Accu-Chek Performa systems that have already been launched in Europe Union, Latin-America, Asia and the Pacific.
Roche recalled a member of the Accu-Chek family in early 2011 when it discovered that its Accu-Chek FlexLink Plus could under-deliver insulin when the tube that delivers the medicine becomes kinked.
Teleflex expands a Class I recall for Maquet Servo 163 humidifiers and beats expectations with its...
Nikon, best known for its cameras, moves into medtech with Optos buy
A single human error in India prompts GE Healthcare to issue a warning on 30 years worth of its MRI...
Staar Surgical posts net losses for the 4th quarter and 2014 but comes close to meeting earnings...